JUL 0 9 2002

HE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Suzuki et al.

Application No.: 10/049,336

Filed: February 4, 2002

For: METHOD FOR MEASURING KINASE ACTIVITY OF CYCLIN/CDK

COMPLEX

Examiner:

Unassigned

Art Unit:

Unassigned

INFORMATION DISCLOSURE

STATEMENT UNDER 37 CFR §1.97 and

§1.98

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed. Also enclosed is a copy of the Preliminary Examination report corresponding to the PCT application. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information, and no inference should be made that the information and references cited are, or are considered to be material to patentability because they are in this statement. No inference should be made that the information and references cited are prior art merely because they are in this statement.

Suzuki et al.

Application No.: 10/049

Page 2

Applicant believes that <u>no fee is required</u> for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Joe Liebeschuetz Reg. No. 37,505

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8th Floor San Francisco, California 94111-3834

Tel: 650-326-2400 Fax: 650-326-2422

JOL:crf

PA 3233891 v1

PTO/SB/08A (10-01)

use through 10/31/2002. OMB 0651-0031 ce: U.S. DEPARTMENT OF COMMERCE

Appro U.S. Patent and Tradem

> C mplete if Kn wn **Application Number** 10/049.336 Filing Date February 4, 2002 First Named Inventor Suzuki Art Unit Unassigned Unassigned **Examiner Name** 082375-000000US Attorney Docket Number

Substitute for form 1449A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)

	U.S. PATENT DOCUMENTS						
		Document Number	Publication Date MM-DD-YYYY				
Examiner	Cite No.1	Number Kind Code ² (if known)		Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document			Name of Patentee or	Pages, Columns, Lines, Where Relevant		
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear	T⁰
	AA	EP	1 184 665	Al	03-06-2002			n/a
	AB	EP	1 050 581	A1	11-08-2000			n/a
				·				<u> </u>

Examiner Signature	Date Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Sheet

of

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

JUL 0 9 2002

Appro U.S. Patent and Tradem

use through 10/31/2002. OMB 0651-0031 ce: U.S. DEPARTMENT OF COMMERCE ct of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449BIPTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

Complete if Kn wn			
Application Number	10/049,336		
Filing Date	February 4, 2002		
First Named Inventor	Suzuki		
Art Unit	Unassigned		
Examiner Name	Unassigned		
Attorney Docket Number	082375-000000US		

OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), to item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-number(s), publisher, city and/or country where published.		T ²		
	AC	AZZI et al., "Interaction between the cell-cycle-control proteins p34 _{cdc2} p9 _{CKShs2} Evidence for two cooperative binding domains in p9 _{CKShs2} ," <u>Eur. J. Biochem.</u> , 203:353-360 (1992).			
	AD	KITAGAWA et al., "The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2," EMBOJ , 15(24):7060-7069 (1996).			
	AE	MEIJER et al., "Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin- dependant kinases cdc2, cdk2 and cdk5," <u>Eur. J. Biochem.</u> , 243:527-536 (1997).			
	AF	VESELY et al., "Inhibition of cyclin-dependant kinases by purine analogues," <u>Eur. J. Biochem.</u> , 224:771-786 (1994).			

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.